MS and Demyelinating Disorders

Researchers investigated a possible quantitative measure of taste function that correlated with myelin-related lesions found in MS patients.

Risk factors regarding MS, including genetic research findings and progressive multifocal leukoencephalopathy while taking natalizumab, are discussed.

Our Feb. news & research include two new migraine drugs, the stroke-Parkinson link, and the potential of an anticancer drug to prevent Alzheimer.

Neuropsychological deficits often remain undiscovered during routine clinical examinations of multiple sclerosis patients due to time constraints.

Our Jan. news & research list includes the possible lingering effects of childhood concussion and the benefits of vitamin D for MS.

New findings regarding viruses and neuronal cells could provide clues for possible new therapies for MS and Alzheimer disease.

Our Dec. news & research list includes groundbreaking research from AES 2015 as well as a few potential neurodegeneration biomarkers.

The holidays can be an especially stressful time of year, so patients need to be aware of how stress influences neurological disease progression.

Our Nov. news & research list includes 2 successful genetic Alzheimer treatments in mouse models and a potential drug for Parkinson disease psychosis.

How can the study of gut microbiota lead to future treatments for neurological disorders?

Encouraging results for many new and future therapies for MS were discussed at ECTRIMS this month.

Our blogger considers a new approach to studying MS and welcomes your thoughts on the subject.

We present findings from 3 recent studies concerning multiple sclerosis research and treatment.

Biomarkers in the blood may be an effective tool for diagnosis and personalized therapy. Learn more about this and two other studies regarding multiple sclerosis.

Recent studies on MS are highlighted, including a possible new avenue for future therapies.

What is the function of continued adult myelination in the normal undiseased brain? A recent study sheds remarkable light on this process and its importance.

Several new studies feature developments in remyelination in MS. Oligodendrocyte precursor cells may be a promising target for MS treatments, and microRNA expression are perhaps an attractive MS biomarker.

Is fatigue with MS related to diet? Is alcohol intake tied to lower MS disability and severity? Researchers at AAN 2015 reported on how patients are affected by what they eat and drink.

Here's a handy synopsis of a “hands-on” review of the current state of monitoring disease and treatment decision making in patients with multiple sclerosis.

Can the EEG predict neurological outcomes in post-anoxic encephalopathy from out-of-hospital cardiac arrest? What effect does TIA have on stroke risk in women migraineurs? What's the relationship between MS and vitamin D levels in minority populations?

A switch to a second-line drug in a patient receiving first-line therapies likely will be effective at decreasing disease activity.

Three brand new studies shed light on use of natalizumab in relapsing-remitting multiple sclerosis.

Do you have a patient with "radiologically isolated syndrome" -- and, if so, what do you tell your patient?

An FDA-approved drug for high blood pressure alleviates clinical symptoms of MS in mice, showing great promise for humans.

Highlights of recent findings about multiple sclerosis are summarized in this slide show.

This treatment may be superior to current treatment for patients with severe multiple sclerosis that is not responding well to standard treatments.

A new study indicates that infection with Helicobacter pylori might lower the risk of multiple sclerosis, at least in women. Pharmaceutical products could provide a novel means of treatment.

The risk of progressive multifocal leukoencephalopathy in patients receiving Tysabri for MS is a concern about this otherwise extremely effective therapy.

HDIT/HCT could induce sustained remission and neurological improvements in patients with multiple sclerosis.

No evidence of disease activity (NEDA) is a new concept developing in MS. The field is beginning to ask how well the new treatments are doing and whether can we ultimately shut down the disease.